Management strategies for posttransplant hypertension.
Despite recent advances in the prolongation of patient and graft survival, transplant patients continue to die prematurely of accelerated cardiovascular disease. Arterial hypertension is a well-known risk factor for cardiovascular disease morbidity and mortality in the general population and a frequent complication following transplantation. The pathogenesis of posttransplant hypertension in renal transplant recipients is multifactorial and includes pretransplant hypertension in the recipient, donor hypertension, uncontrolled renin secretion from the remaining native kidney, hypertension as a consequence of graft dysfunction, recurrent or de novo renal disease, and, nowadays more rarely, transplant artery stenosis. The strong impact of an immunosuppressive regimen consisting of calcineurin inhibitors and steroids must also be considered. Calcineurin inhibitors and corticosteroids induce hypertension in renal, cardiac, liver, bone marrow, and lung transplant recipients. Posttransplant hypertension appears to be a major risk factor for graft and patient survival. Recent controlled studies support the opinion that posttransplant hypertension must be treated as strictly as in a population with essential hypertension, diabetes mellitus, or chronic renal failure.